CN Patent

CN107334734B — 一种西罗莫司或其衍生物的眼用制剂

Assigned to Zhejiang University ZJU · Expires 2020-03-17 · 6y expired

What this patent protects

本发明公开了一种西罗莫司或其衍生物的眼用制剂，包括以下重量百分比的原料：依维莫司或西罗莫司0.02～0.2％；溶剂0～3％；乳化剂和表面活性剂0～7％；渗透压调节剂0～8％；pH调节剂0～0.5％；抑菌剂0～5％；增稠剂0～2％；纯化水余量。其中，溶剂组分与乳化剂和表面活性剂组分不同时为零。本发明西罗莫司或其衍生物的眼用制剂制备简便，适于工业化生产，应用方便，具有良好的应用前景。

USPTO Abstract

本发明公开了一种西罗莫司或其衍生物的眼用制剂，包括以下重量百分比的原料：依维莫司或西罗莫司0.02～0.2％；溶剂0～3％；乳化剂和表面活性剂0～7％；渗透压调节剂0～8％；pH调节剂0～0.5％；抑菌剂0～5％；增稠剂0～2％；纯化水余量。其中，溶剂组分与乳化剂和表面活性剂组分不同时为零。本发明西罗莫司或其衍生物的眼用制剂制备简便，适于工业化生产，应用方便，具有良好的应用前景。

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

Patent Metadata

Patent number: CN107334734B
Jurisdiction: CN
Classification: —
Expires: 2020-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Zhejiang University ZJU
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.